Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
about
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerTargeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.Chemotherapy induces ovarian cancer cell repopulation through the caspase 3-mediated arachidonic acid metabolic pathway.Current treatment strategies for advanced prostate cancer.A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer.Editorial Comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
P2860
Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Cytotoxic chemotherapy in the ...... stant prostate cancer (mCRPC).
@en
type
label
Cytotoxic chemotherapy in the ...... stant prostate cancer (mCRPC).
@en
prefLabel
Cytotoxic chemotherapy in the ...... stant prostate cancer (mCRPC).
@en
P2093
P2860
P356
P1433
P1476
Cytotoxic chemotherapy in the ...... stant prostate cancer (mCRPC).
@en
P2093
Andrew J Armstrong
Christopher G Wang
Guru Sonpavde
Matthew D Galsky
William K Oh
P2860
P356
10.1111/BJU.12867
P577
2014-10-23T00:00:00Z